Cellectis (CLLS) EBITDA (2015 - 2026)

Cellectis' EBITDA history runs 12 years deep, the most recent figure standing at -$25.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 77.49% year-over-year to -$25.2 million; the TTM figure through Mar 2026 stood at -$44.1 million (up 16.61% YoY), while the FY2025 annual figure was -$59.6 million, changed 0.0% from the prior year.
• EBITDA was -$25.2 million for Q1 2026 at Cellectis, down from -$17.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.0 million in Q3 2025 to a low of -$29.6 million in Q4 2023.
• Historically, EBITDA has averaged -$17.9 million across 5 years, with a median of -$20.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA plunged 422.6% in 2023, then surged 174.67% in 2025.
• A 5-year view of EBITDA shows it stood at -$5.7 million in 2022, then slumped by 422.6% to -$29.6 million in 2023, then soared by 63.89% to -$10.7 million in 2024, then sank by 62.47% to -$17.4 million in 2025, then tumbled by 45.04% to -$25.2 million in 2026.
• The last three EBITDA figures came in at -$25.2 million (Q1 2026), -$17.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.